AbbVie Inc. (ETR:4AB)
Germany
· Delayed Price · Currency is EUR 158.40
+3.60 (2.33%)
Apr 24, 2025, 5:35 PM CET
AbbVie Revenue
In the year 2024, AbbVie had annual revenue of $56.33B USD with 3.71% growth. AbbVie had revenue of $15.10B in the quarter ending December 31, 2024, with 5.60% growth.
Revenue
$56.33B
Revenue Growth
+3.71%
P/S Ratio
5.16
Revenue / Employee
$1.02M
Employees
55,000
Market Cap
281.01B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.16B |
| Siemens Healthineers AG | 22.67B |
| Fresenius SE & Co. KGaA | 21.83B |
| Bayer Aktiengesellschaft | 46.61B |
| Sartorius Aktiengesellschaft | 3.44B |
| Fresenius Medical Care AG | 19.34B |
| Carl Zeiss Meditec AG | 2.08B |
| Fielmann Group AG | 2.16B |
AbbVie News
- 5 hours ago - Lost Money on Cerevel Therapeutics Holdings, Inc.(ABBV)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewsWire
- 6 hours ago - AbbVie Q1 2025 Earnings Preview - Seeking Alpha
- 7 hours ago - A Glimpse of AbbVie's Earnings Potential - Benzinga
- 8 hours ago - AbbVie submits marketing application to FDA for short term frown lines treatment - Seeking Alpha
- 8 hours ago - Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV - Accesswire
- 9 hours ago - AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines - PRNewsWire
- 12 hours ago - The Gross Law Firm Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV - PRNewsWire
- 1 day ago - Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV - GlobeNewsWire